TheraVida

TheraVida develops innovative pharmaceutical solutions targeting hyperhidrosis, focusing on its proprietary product Anhydrix™ to provide effective treatment options for excessive sweating. Founded in 2005, TheraVida is headquartered in Mountain View, US, specializing in therapeutic solutions for hyperhidrosis. The company raised USD 1. 06 million in Series A funding in March 2012, with investors including Sanderling Ventures.

TheraVida has completed two deals to date, with a current valuation of USD 25. 755 mn. TheraVida, Inc. primarily offers Anhydrix™, a proprietary and patent-protected pharmaceutical product designed to treat primary focal hyperhidrosis, characterized by excessive sweating beyond natural thermal regulation.

Anhydrix™ uses a unique combination drug technology to enhance tolerability while maintaining efficacy. Targeting the U. S. market, TheraVida aims to address the needs of patients suffering from hyperhidrosis, providing effective treatment options for both patients and healthcare providers.

TheraVida’s revenue structure is based on the development and commercialization of Anhydrix™, the only oral, systemically acting drug for primary focal hyperhidrosis currently in development. Revenue generation is expected through partnerships with healthcare providers and pharmacies, as well as a potential direct-to-consumer model once the product is launched. Specific pricing plans for Anhydrix™ have not been disclosed, but revenue will likely reflect its positioning as a specialty pharmaceutical product aimed at improving the quality of life for patients. TheraVida plans to leverage the recent Series A funding of USD 1.

06 million raised in March 2012 to support the further development of Anhydrix™. The company is set to broaden its market presence and anticipates launching Anhydrix™ in the U. S. market in the near future.

Additional geographic expansion into international markets is under consideration, although specific regions and timelines have not been detailed.